FDA Wants Another Trial Of Genta’s Genasense For CLL
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s complete response letter requesting another trial concludes the agency’s review of an amended NDA submitted after an unsuccessful appeal of a “not approvable” letter.
You may also be interested in...
FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter
Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.
FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter
Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.
Genta Gets New FDA Action Date For Genasense In CLL
Firm has SPA for additional trial pending at agency, chairman said in an interview.